Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.

Date

2016

Author

Butzkueven, H.
Spelman, T.
Kalincik, T.
Jokubaitis, V.
Zhang, A.
Pellegrini, F.
La Spitaleri, D.

Metadata

Show full item record

Abstract

…

Source

Multiple Sclerosis Journal

Volume

22

Issue

3

URI

https://hdl.handle.net/20.500.12712/13472

Collections